UK Markets open in 6 hrs 1 min
  • NIKKEI 225

    -192.71 (-0.69%)

    +84.09 (+0.46%)

    +0.78 (+1.00%)

    +3.50 (+0.20%)
  • DOW

    +3.07 (+0.01%)

    +457.28 (+3.35%)
  • CMC Crypto 200

    +12.67 (+3.26%)
  • Nasdaq

    -65.72 (-0.59%)
  • ^FTAS

    +13.81 (+0.34%)

Original-Research: Ikonisys SA (von Sphene Capital GmbH)

Original-Research: Ikonisys SA - von Sphene Capital GmbH Einstufung von Sphene Capital GmbH zu Ikonisys SA Unternehmen: Ikonisys SA ISIN: FR00140048X2 Anlass der Studie: Update Report Empfehlung: Buy seit: 31.10.2022 Kursziel: EUR 6,70 (unverändert) Kursziel auf Sicht von: 24 Monate Letzte Ratingänderung: - Analyst: Peter Thilo Hasler, CEFA H1/2022 in-line with our expectations Following the publication of the H1/2022-report, we are slightly adjusting our revenue and earnings forecasts. After refreshing the valuation-relevant risk parameters, we calculate an unchanged target price of EUR 6.70 from our three-stage DCF entity model (base case scenario). In a Monte Carlo analysis we used alternative sales and earnings scenarios and calculated equity values in a range between EUR 67.3m (10% quantile) and EUR 96.9m (90% quantile), which translates into price targets between EUR 5.30 and EUR 7.60 per share (fully diluted), respectively. An alternative economic profit model supports the results of the DCF model, with price targets between EUR 5.20 (based on the economic profit of the year 2025e) and EUR 7.40 (economic profit 2026e, secondary valuation methods). Based on a 24-month expected upside potential of 311.0%, we confirm our Buy rating for the shares of Ikonisys SA. In the first half of the year, Ikonisys generated revenues of EUR 0.207m. Revenues from product sales of Ikoniscope microscopes and the included software application amounted to EUR 0.109m, while maintenance services from technical support were EUR 0.098m. Revenues were mainly generated from the sale of the complete solution to Comprehensive Urology, an established user of the former Ikoniscope Gen1 platform. The fact that this customer is now also buying Ikonisys' reagents confirms, in our view, Ikonisys' business model, which is based on a commercial all-in-one solution which will primarily be sold into the existing client-base. The operating result (EBIT) for the first half of 2022 was EUR -1.016m, in line with our expectations. At the end of the first half-year, the net financial position of the company was EUR 0.204m. Additional financing needs can be filled with the recently concluded financing agreement with Atlas Capital Markets totalling EUR 5.1m. In addition to a distribution agreement Ikonisys has signed with Biovendor Laboratory Medicine for countries where Ikonisys will not establish direct sales channels, the most notable event of recent weeks is the sale of an Ikoniscope20 solution to one of the largest urology organisations in the US with a physician network that spans more than ten states and treats more than 700,000 patients annually. The Ikoniscope20 solution will be used to automate the early detection of bladder cancer. Die vollständige Analyse können Sie hier downloaden: Kontakt für Rückfragen Peter Thilo Hasler, CEFA +49 (89) 74443558/ +49 (152) 31764553 -------------------übermittelt durch die EQS Group AG.------------------- Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.